Oncologists call for reduction in drug prices

A report in the journal Blood finds 11 of 12 cancer drugs approved by the FDA last year cost more than $100,000 annually, making it difficult for patients to obtain treatment for conditions such as chronic myeloid leukemia. It's part of a broader trend of high-cost treatments, researchers noted, reporting that the mean monthly cost of cancer drugs overall has increased from $5,000 to more than $10,000 in the past decade. More than 100 of the world's leading cancer specialists urged drug companies to address the issue, arguing that the prices are unsustainable. "Advocating for lower drug prices is a necessity to save the lives of patients," they wrote.

View Full Article in:

New York Times (tiered subscription model), The · U.S. News & World Report

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC